XJPX
4928
Market cap1.01bUSD
Dec 05, Last price
4,590.00JPY
1D
-0.86%
1Q
-0.97%
Jan 2017
25.41%
IPO
384.69%
Name
Noevir Holdings Co Ltd
Chart & Performance
P/E
19.67
P/S
2.46
EPS
233.34
Div Yield, %
4.79%
Shrs. gr., 5y
—
Rev. gr., 5y
1.50%
Revenues
63.82b
+2.03%
Net income
7.97b
+3.87%
CFO
9.12b
+19.66%
Dividend
Sep 29, 20250 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Noevir Holdings Co., Ltd. develops, produces, and sells cosmetics, pharmaceuticals, and health food products in Japan, China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, the United States, Canada, and Russia. The company's Cosmetics segment develops, produces, and sells skincare products under various brands, including Noevir and Nameraka Honpo; and NOV hypoallergenic cosmetics, as well as provides contract manufacturing services for cosmetics and quasi drugs. Its Pharmaceutical & Health Food segment produces and sells Nanten Nodo Ame cough drops; functional drinks, such as the Min Min Da Ha; and over-the-counter pharmaceuticals comprising cold remedies, eye drops, and digestive aids, as well as nutritional supplements, and other products. The company's Other segment sells and leases apparels and aircrafts. The company also produces and sells toiletries; purchases and sells makeup products and vessels; and provides market research services. In addition, it provides air transportation, charter flights, ground handling, and hanger rental services; and aircraft flight training, as well as undertakes aviation-related operations. The company sells its products through drug stores, specialty goods and general merchandise stores, supermarkets, online stores, and convenience stores, as well as approximately 2,000 Noevir beauty studios and own retail stores. Noevir Holdings Co., Ltd. was founded in 1964 and is headquartered in Tokyo, Japan.
IPO date
Mar 22, 2011
Employees
1,398
Domiciled in
JP
Incorporated in
JP
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | 2016‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||